News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
190 Results
Type
Article (16)
Press Release (174)
Section
Business (85)
Deals (18)
Drug Development (19)
News (107)
Policy (2)
Tag
Alliances (1)
Clinical research (14)
Compensation (1)
Data (1)
Diagnostics (1)
Earnings (24)
Events (51)
Healthcare (2)
IPO (17)
Mergers & acquisitions (1)
NextGen Class of 2024 (4)
People (55)
Phase I (9)
Phase II (8)
Phase III (2)
Preclinical (1)
Regulatory (2)
Startups (4)
United States (10)
Date
Last 30 days (2)
Last 365 days (26)
2024 (24)
2023 (37)
2022 (33)
2021 (38)
2020 (34)
2019 (9)
2018 (9)
2017 (3)
2016 (1)
2015 (2)
Location
Asia (2)
Delaware (1)
Europe (25)
Massachusetts (9)
190 Results for "replimune".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Genetown
Replimune to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
Replimune Group, Inc. announced that Sushil Patel, Chief Executive Officer of Replimune, will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024 at 2:00 PM ET.
June 7, 2024
·
1 min read
Press Releases
Replimune to Present at Two Upcoming Investor Conferences
October 2, 2024
·
1 min read
Genetown
Replimune Announces $100 Million Private Placement Financing
Replimune Group, Inc. announced that it has entered into a securities purchase agreement for a private investment in public equity that is expected to result in gross proceeds of approximately $100 million to the Company before deducting placement agent fees and offering expenses.
June 13, 2024
·
5 min read
Press Releases
Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
October 30, 2024
·
4 min read
Genetown
Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Replimune Group Inc. announced multiple presentations at the 2024 American Society of Clinical Oncology Annual Meeting being held in Chicago from May 31-June 4, 2024.
May 23, 2024
·
5 min read
Genetown
Replimune to Present at Three Upcoming Investor Conferences - March 5, 2024
Replimune Group, Inc. today announced that members from the Replimune management team will present and host investor meetings at the following three conferences.
March 5, 2024
·
1 min read
Business
Replimune Reports Fiscal Fourth Quarter and Year Ended 2024 Financial Results and Provides Corporate Update
Replimune Group today announced financial results for the fiscal fourth quarter and year ended March 31, 2024 and provided a business update.
May 16, 2024
·
11 min read
Press Releases
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 9, 2024
October 10, 2024
·
2 min read
Deals
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Replimune Group, Inc. today announced the grant of inducement equity awards to Carolyn Trott, the Company’s newly appointed Senior Vice President, Quality Assurance.
April 4, 2024
·
4 min read
Business
Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions
Replimune Group, Inc. announced changes to its executive leadership team designed to support the Company’s preparations for the commercial launch of RP1, pending regulatory submission and approval in anti-PD1 failed melanoma.
March 26, 2024
·
5 min read
1 of 19
Next
